[Durable Response after Discontinuation Due to Immune-Related Adverse Events in a Patient with Metastatic Clear Cell Renal Cell Carcinoma : A Case Report].

Abstract

A 70-year-old female with metastatic clear cell renal cell carcinoma was treated with nivolumab. After three dosages, she developed interstitial lung disease which required steroid therapy and nivolumab was discontinued. Thereafter, the target lesion continued to shrinkand the best response was partial response 15 weeks after discontinuation of nivolumab, the reduction rate of which eventually reached 49.1%. Other immune-related adverse events (irAEs), nephrotic syndrome and acute kidney injury developed 34 weeks after discontinuation of nivolumab, leading to irreversible kidney injury that required chronic hemodialysis. Although the target lesion continued to shrink, a new lesion developed 48 weeks after discontinuation of nivolumab. Subsequently, targeted therapies were added, but she died of cancer 13 months after resuming medical treatment. In this case, although various irAEs developed, the effectiveness of nivolumab was sustained even after it was discontinued.

• Authors: Yohei Ueki, Toshiaki Tanaka, Kohei Hashimoto, Ko Kobayashi, Fumimasa Fukuta, Naoya Masumori
• Journal: Hinyokika kiyo. Acta urologica Japonica (Hinyokika Kiyo) Vol. 66 Issue 5 Pg. 147-151 (May 2020) ISSN: 0018-1994 [Print] Japan
• PMID: 32483950 (Publication Type: Case Reports, Journal Article)

Chemical References

• Nivolumab

Topics

• Aged
• Carcinoma, Renal Cell
• Female
• Humans
• Kidney Neoplasms
• Lung Diseases, Interstitial
• Nivolumab